News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Bets On New Therapeutic Uses Of Known Molecules


12/9/2013 6:50:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Teva Pharmaceutical Industries, the world's biggest maker of generic drugs, estimates its pipeline of so-called new therapeutic entities (NTEs) could generate revenue of $1 billion to $1.5 billion by 2018. This figure could jump to $3 billion in 2020, Elisabeth Kogan, Teva's senior vice president of generic research and development, told reporters on Sunday. NTEs are based on known molecules that are formulated, delivered or used in new ways to address unmet patient needs.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters


comments powered by Disqus
Reuters
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES